Drug intelligence / Profile preview

KS101

Development stage: Phase 1
Lead developer: Klotho Sciences Australia Pty Ltd.
Modality: Small Molecules
Administration: Oral

Overview

KS101 is an investigational oral small molecule drug being evaluated in a Phase 1 clinical trial for safety, tolerability, and pharmacokinetics in healthy volunteers. The primary goal is to assess its effects and optimal dosing, with a focus on potential applications for age-related diseases including chronic kidney disease and Alzheimer's disease. The study is a three-part, randomized, placebo-controlled design, involving single and multiple ascending doses, as well as food effect evaluation. The development status for the main indications is investigational, and the molecule is still under early-phase clinical evaluation, with full mechanism and proprietary details not yet disclosed.[2]

Brand names: KS101KS-101KS 101
Other names: KS101KS-101KS 101

Beyond the preview

Go deeper on KS101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KS101.

Explore the full profile